Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy |
| |
| Authors: | Zi-Yi Zhu Yong-An Meng Bin Yan Jing Luo |
| |
| Affiliation: | Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China,Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China,Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China and Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China; Hunan Clinical Research Center of Ophthalmic Disease, Changsha 410011, Hunan Province, China |
| |
| Abstract: | In recent years, retinal ischemia such as that which occurs in diabetic retinopathy (DR) and retinal vein occlusion (RVO) has become a hotspot of ischemic retinopathy research. High levels of vascular endothelial growth factor (VEGF) are recognized as a major cause of macular edema (ME) in DR and RVO. High concentrations of VEGF in the vitreous can lead to serious retinal ischemia and hypoxia and form retinal nonperfusion areas (NPAs). Different levels of retinal ischemia can represent disease severity and progression. Anti-VEGF therapy as the first-line treatment for ME has been found to be effective in improving vision, but there are still disputes about whether anti-VEGF therapy could improve retinal ischemia and achieve reperfusion of previously developed retinal NPAs. Here, we review and summarize studies of the effects of anti-VEGF drugs on retinal ischemia, especially NPAs. |
| |
| Keywords: | anti-vascular endothelial growth factor retinal nonperfusion areas ischemic retinopathy macular ischemia |
|
| 点击此处可从《国际眼科》浏览原始摘要信息 |
|
点击此处可从《国际眼科》下载全文 |
|
